Inari Medical, Inc. (NASDAQ:NARI) Shares Sold by Bessemer Group Inc.

Bessemer Group Inc. trimmed its position in Inari Medical, Inc. (NASDAQ:NARI) by 72.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 737 shares of the company’s stock after selling 1,903 shares during the quarter. Bessemer Group Inc.’s holdings in Inari Medical were worth $37,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of NARI. Sei Investments Co. raised its position in Inari Medical by 1.3% during the 4th quarter. Sei Investments Co. now owns 57,566 shares of the company’s stock worth $2,939,000 after buying an additional 727 shares during the last quarter. Jane Street Group LLC raised its holdings in shares of Inari Medical by 32.4% during the third quarter. Jane Street Group LLC now owns 95,223 shares of the company’s stock worth $3,927,000 after purchasing an additional 23,286 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Inari Medical by 66.8% during the fourth quarter. GAMMA Investing LLC now owns 1,963 shares of the company’s stock worth $100,000 after purchasing an additional 786 shares during the last quarter. Barclays PLC lifted its position in Inari Medical by 9.7% during the third quarter. Barclays PLC now owns 288,079 shares of the company’s stock valued at $11,881,000 after purchasing an additional 25,365 shares during the period. Finally, Legato Capital Management LLC purchased a new stake in Inari Medical in the fourth quarter valued at $681,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

Inari Medical Price Performance

Shares of NASDAQ NARI opened at $79.97 on Friday. The firm has a market cap of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02. The company’s 50-day simple moving average is $79.96 and its 200-day simple moving average is $65.21. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $79.99.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on NARI shares. William Blair reissued a “market perform” rating on shares of Inari Medical in a report on Tuesday, January 7th. BTIG Research restated a “neutral” rating on shares of Inari Medical in a research report on Wednesday, January 8th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $80.00 price objective (up previously from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Baird R W cut shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 7th. Finally, Wells Fargo & Company reissued an “equal weight” rating and set a $80.00 price target (up from $65.00) on shares of Inari Medical in a report on Tuesday, January 7th. Twelve research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $68.00.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.